Document Detail


A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
MedLine Citation:
PMID:  1714949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Using a loading dose/continuous infusion schedule, fludarabine phosphate was administered to 51 patients with previously treated chronic lymphocytic leukemia (CLL). All patients had evidence of active disease, and the majority had advanced Rai stages. Of the 42 patients assessable for response, 22 (52%) achieved a partial response, five (12%) had stable disease, and 15 (36%) progressed. Thirteen of the 22 responders improved their Rai stages with fludarabine therapy, including six patients who achieved stage 0. Response rates for pretreatment stages III and IV were 60% and 53%, respectively. Patients with final Rai stages 0 to II had better survival than those with stages III and IV. Patients who had undergone splenectomy before starting therapy were more likely to respond. Myelosuppression was the primary toxicity and did not appear to be cumulative. Severe leukopenia and thrombocytopenia, although infrequent, were associated with several deaths in the early cycles of treatment. Nonhematologic toxicity was mild with no serious neurotoxicity noted. Infections were common with 22 minor, 18 major, and 10 fatal episodes. Fludarabine phosphate by this alternative dosing schedule is effective in refractory advanced CLL and is well tolerated by the majority of patients.
Authors:
C A Puccio; A Mittelman; S M Lichtman; R T Silver; D R Budman; T Ahmed; E J Feldman; M Coleman; P M Arnold; Z A Arlin
Related Documents :
23450449 - Current concepts in the diagnosis and management of poorly differentiated gastrointesti...
23544739 - Management of incidental and non-incidental papillary thyroid microcarcinoma.
8083719 - Chronic lymphocytic leukemia: an updated review.
24528219 - Prolonged progression-free survival and preserved quality of life in the canadian prosp...
24299319 - Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranod...
23295939 - The impact of geographic variations in treatment on outcomes in ovarian cancer.
22493359 - Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer ...
9334609 - Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience.
1614589 - Failure of conventionally fractionated radiotherapy to decrease the risk of hemorrhage ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  9     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1991 Sep 
Date Detail:
Created Date:  1991-09-26     Completed Date:  1991-09-26     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1562-9     Citation Subset:  IM    
Affiliation:
New York Medical College, Valhalla, 10595.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage*,  adverse effects
Combined Modality Therapy
Drug Administration Schedule
Drug Evaluation
Female
Humans
Infusions, Intravenous
Injections, Intravenous
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*,  therapy
Male
Middle Aged
Vidarabine Phosphate / administration & dosage,  adverse effects,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 1X9VK9O1SC/fludarabine phosphate; 29984-33-6/Vidarabine Phosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testic...
Next Document:  Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disea...